Skip to main content
NCBI home page
Taylor & Francis - PMC COVID-19 Collection logoLink to Taylor & Francis - PMC COVID-19 Collection
. 2005 Feb 23;4(6):827–836. doi: 10.1517/14712598.4.6.827

Role of interferons in the treatment of severe acute respiratory syndrome

Jindrich Cinatl Jr 1, Martin Michaelis 1, Martin Scholz 1, Hans Wilhelm Doerr 1
PMCID: PMC7103669  PMID: 15174965

Abstract

Severe acute respiratory syndrome (SARS) is caused by the SARS coronavirus (SCV). The disease appeared in the Guandong province of southern China in 2002. The epidemic affected > 8422 patients and caused 908 deaths in 29 countries on 5 continents. Several treatment modalities were tried with limited success to treat SARS and a variety of experimental drugs are under development. Type I interferons (IFNs-α/β) were suggested as potential candidates to treat SARS. Several animal and human coronaviruses, including SCV, were shown to be sensitive to IFNs both in vitro and in vivo. A pilot clinical report showed effectiveness of IFN-α for the treatment of SARS patients. This review summarises antiviral activities of IFNs with special regard to SARS, and reviews the published clinical and experimental data describing the use of IFNs for SARS.

Keywords: interferon, SARS, SARS coronavirus

Bibliography

  • 1.STADLER K, MASIGNANI V, EICKMANN M et al.: SARS-beginning to understand a new virus. Nat. Rev Microbiol. (2003) 1:209–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.PEIRIS JS, YUEN KY, OSTERHAUS AD, STOHR K: The severe acute respiratory syndrome. N Engl. J. Med. (2003) 349:2431–2441. [DOI] [PubMed] [Google Scholar]
  • 3.VASTAG B: Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA (2003) 290:1695–1696. [DOI] [PubMed] [Google Scholar]
  • 4.DAVIDSON A, SIDDELL S: Potential for antiviral treatment of severe acute respiratory syndrome. Carr: Opin. Infect. Dis. (2003) 16:565–571. [DOI] [PubMed] [Google Scholar]
  • 5.LEE N, HUI D, WU A et al.: A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl. J. Med. (2003) 348:1986–1994. [DOI] [PubMed] [Google Scholar]
  • 6.LOUTFY MR, BLATT LM, SIMINOWITCH KA et al.: Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome. JAMA (2003) 290:3222–3228. [DOI] [PubMed] [Google Scholar]
  • •Preliminary, uncontrolled study of patients with SARS using treatment with IFN alfacon-1 improved disease outcome.
  • 7.POUTANEN SM, LOW DE, HENRY B et al.: Identification of severe acute respiratory syndrome in Canada. N Engl. J. Med. (2003) 348:1995–2005. [DOI] [PubMed] [Google Scholar]
  • 8.SO LK, LAU AC, YAM LY et a/.: Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet (2003) 361:1615–.1617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.TSANG KW, HO PL, 001. GC et al: A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl. J. Med; (2003) 348:1977–1985. [DOI] [PubMed] [Google Scholar]
  • 10.ZHAO Z, ZHANG F, XU M et al.: Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. (2003) 52:715–720. [DOI] [PubMed] [Google Scholar]
  • •First clinical trial describing use of IFN-a for SARS.
  • 11.BOOTH CM, MATUKAS LM, TOMLINSON GA et al.: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JA/VIA (2003) 289:2801–2809. [DOI] [PubMed] [Google Scholar]
  • 12.CINATL J JR, MORGERNSTERN B, BAUER G, CHANDRA P, RABENAU H, DOERR HW : Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet (2003) 361:2045–2046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.CHU CM CHENG VCC, HUNG IFN et al.: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Vaccine (2004) 59:252–256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.SUI J, WENHUI L, MURAKAMI A et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to 51 protein that blocks receptor association. Proc. Nati Acad. Sci. USA (2004) 101:2536–2541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.ZHANG Y, LI T, FU L et al.: Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. FEBS Lett. (2004) 560:141–146. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 16.CINATL J JR, MORGERNSTERN B, BAUER G, CHANDRA P, RABENAU H, DOERR HW : Treatment of SARS with human interferons. Lancet (2003) 362:293–294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • •First in vitro study that reports on the effects of IFNs on SCV replication; comparison of different I...PNs in two different cell culture systems.
  • 17.HAAGMANS BL, KUIKEN T, MARTINA BE et al.: Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004. 10:290–293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • •Demonstration that pegylated INF-a protects type 1 pneumocytes from SCV infection in cynomolgus macaques.
  • 18.HENSLEY LE, FRITZ EA, JAHRLING PB et al.: Interferon-13 la and SARS coronavirus replication. Emerg. Infect. Dis. (2004) 10:317–319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • •Investigation of the influence of IFN-I3-la on SCV replication in Vero cells.
  • 19.SEN GC: Viruses and interferons. Annu. Rev. Microbiol. (2001) 55:255–281. [DOI] [PubMed] [Google Scholar]
  • 20.KATZE MG, HE Y, GALE M JR: Viruses and interferon: a fight for supremacy. Nat. Rev Immunol. (2002) 2:675–687. [DOI] [PubMed] [Google Scholar]
  • 21.UROSEVIC N: Is flavivirus interferon type I-independent? Immunol. Cell Biol. (2003) 81:224–229. [DOI] [PubMed] [Google Scholar]
  • 22.SHUAI K, LIU B: Regulation olJAK-STAT signalling in the immune system. Nat. Rev Immunol. (2003) 3:900–911. [DOI] [PubMed] [Google Scholar]
  • 23.KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J, SCHINDLER CW: Signalling through the JAK/STAT pathway, recent advances and future challenges. Gene (2002) 285:1–24. [DOI] [PubMed] [Google Scholar]
  • 24.LEVY DE: Whence interferon? Variety inthe production of interferon in response to viral infection. J. Exp. Med. (2002) 195:F15–F18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.DE VEER MJ, HOLKO M, FREVEL M et al.: Functional classification of interferon-stimulated genes identified using microarrays. Leukoc. Biol. (2001) 69:912–920. [PubMed] [Google Scholar]
  • 26.DER SD, ZHOU A, WILLIAMS BR, SILVERMAN RH: Identification of genes differentially regulated by interferon a,3, or using oligonucleotide arrays. Proc. Nati Acad. ScL USA (1998) 95:15623–15628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.SAMUEL C: Antiviral action of interferons. Clin. Microbiol. Rev (2001) 14:778–809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.ZHOU A, PARANJAPE JM, WILLIAMS BR, SILVERMAN RH: Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology (1999) 258:435–440. [DOI] [PubMed] [Google Scholar]
  • 29.ESKILDSEN E, JUSTESEN J, SCHIERUP MH, HARTMANN R: Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family. Nucleic Acids Res. (2003) 31:3166–3173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.GOODBOURN S, DIDCOCK L, RANDALL RE: Interlerons: cell signalling. Immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. (2000) 81:2341–2364. [DOI] [PubMed] [Google Scholar]
  • 31.CHAWLA-SARKAR M, LINDNER DJ, LIU YF et a/.:Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 8:237–249. [DOI] [PubMed] [Google Scholar]
  • 32.PATEL RC, SEN GC: PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. (1998) 17:4379–4390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.ABRAHAM N, STOJDL DF, DUN CAN PI et al.: Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. [Biol. Chem. (1999) 274:5953–5962. [DOI] [PubMed] [Google Scholar]
  • 34.BALACHANDRAN S, ROBERTS PC, BROWN LE et al.: Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity (2000) 13:129–141. [DOI] [PubMed] [Google Scholar]
  • 35.HALLER 0, ACKLIN M, STAEHELI P:Influenza virus resistance of wild mice: wild-type and mutant Mx allels occur at comparable frequencies. J. Interferon Res. (1987) 7:647–656. [DOI] [PubMed] [Google Scholar]
  • 36.STAEHLI P: Interferon-induced proteins and the antiviral state. Adv. Virus Res. (1990) 38:147–200. [DOI] [PubMed] [Google Scholar]
  • 37.HALLER 0, KOCHS G: Interferon-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic (2002) 3:710–717. [DOI] [PubMed] [Google Scholar]
  • 38.JANZEN C, KOCHS G, HALLER 0: A monomeric GTPase-negative MxA mutant with antiviral activity. J. Vim/. (2000) 74:15427–15432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.ANDERSON SL, CARTON JM, LOU J, XING L, RUBIN BY: Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology (1999) 256:8–14. [DOI] [PubMed] [Google Scholar]
  • 40.PATTERSON JB, THOMIS DC, HANS SL, SAMUEL CE: Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology (1995) 210:508–511. [DOI] [PubMed] [Google Scholar]
  • 41.SAUNDERS LR, BARBER GN: The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB (2003) 17:961–983. [DOI] [PubMed] [Google Scholar]
  • 42.LIU Y, EMERSON RB, SAMUEL CE: Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice variants of the interferon inducible double-stranded RNA-specific adenosinase ADAM,. j Biol. Chem. (1999) 274:18351–18358. [DOI] [PubMed] [Google Scholar]
  • 43.JAYAN GC, CASEY JL: Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. I Virol (2002) 76:3819–3827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.SPERBER SJ, HAYDEN FG: Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J. Interferon Res. (1989) 9:285–293. [DOI] [PubMed] [Google Scholar]
  • 45.PEI J, SEKELLICK MJ, MARCUS PI, CHOI IS, COLLISON EW: Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory ilness. J. Interferon Cytokine Res. (2001) 21:1071–1077. [DOI] [PubMed] [Google Scholar]
  • 46.MINAGAWA H, TAKENAKA A, MOHRI S, MORI R: Protective effect of recombinant interferon beta against mouse hepatitis virus infection. Antiviral Res. (1987) 8:85–95. [DOI] [PubMed] [Google Scholar]
  • 47.LUCCHIARI MA, MARTIN JP, MOD OLELL M, PEREIRA CA: Acquired immunity of A/J mice to mouse hepatitis virus 3 infection: dependence on interferon-gamma synthesis and macrophage sensitivity to interferon-gamma." Gen. Viral. (1991) 72:1317–1322. [DOI] [PubMed] [Google Scholar]
  • 48.WEINGARTL HM, DERBSHIRE JB: Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta. Can. J. Vet. Res (1991) 55:143–149. [PMC free article] [PubMed] [Google Scholar]
  • 49.COLLINS AR: Interferon gamma potentiates human coronavirus 0C43 infection of neuronal cells by modulation of HLA class I expression. Immunol Invest. (1995) 24:977–986. [DOI] [PubMed] [Google Scholar]
  • 50.HERTZIG T, SCANDELLA E, SCHELLE B et al: Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J. Gen. Virol (2004) (In Press). [DOI] [PubMed]
  • 51.FUCHIZAKI U, KANEKO S, NAKAMOTO Y et al.: Synergistic antiviral effect of a combination of mouse interferon-a and interferon-y on mouse hepatitis virus. J. Med. Viral. (2003) 69:188–194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.BAUDOUX P, CARRAT C, BESNARDEAU L, CHARLEY B, LAUDE H: Coronavirus psedoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. Viral. (1998) 72:8636–8643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.COLLINS AR: Comparison of the replication of distinct strains of human coronavirus 0C43 in organotypic human colon cells (Caco-2) and mouse intestine. Adv. Exp. Med. Biol. (1990) 276:497–503. [DOI] [PubMed] [Google Scholar]
  • 54.PITKARANTA A, NOKSO-KOIVISTO J, JANTTI V, TAKALA A, KILPIT, HOVI T: Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J. Gin Virol (1999) 14:199–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.TURNER RB, FELTON A, KOSAK K, KELSEY DK, MESCIEVITZ CK: Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J. Infect. Dis. (1986) 154:443–447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.TYRRELL DA: The efficacy and toleranceof intranasal interferons: studies at the Common Cold Unit. I Antimicrob. Chemother. (1986) 18:153–156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.MELIAN EB, PLOSKER GL: Interferon alfacon-1. Drugs (2001) 61: 1661-1691. [DOI] [PubMed] [Google Scholar]
  • 58.ENSERINK M: Interferon shows promisein monkeys. Science (2004) 303:1273–1275. [DOI] [PubMed] [Google Scholar]
  • 59.HARLE P, LAURET E, PITHA PM, DE MAEYER E, CARR DJ: Expression of human and macaque type I IFN transgenes interferes with HSV- replication at the transcriptional and translational levels: IFN-B is more potent than IFN-a2. Virology (2001) 290:237–248. [DOI] [PubMed] [Google Scholar]
  • 60.ANTONETTI F, FINOCCHIARO 0, MASCIA M, TERLIZZESE MG, JABER A: A comparison of the biological activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. (2002) 22:1181–1184. [DOI] [PubMed] [Google Scholar]
  • 61.ANTONELLI G, SCAGNOLARI C, VINCENZI E, CLEMENTI H: Treatment of SARS with human interferons. Lancet (2003) 362:1158; author reply 1158–1159. [DOI] [PMC free article] [PubMed]
  • 62.STROHER U, DICARO A, STRONG JEet al.: Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J. Infect. Dis. (2004) 189:1164–1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.TAN ELC, 001. EE, LIN C-Y et al: Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis; (2004) 10:581–586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.MANNS MP, CORNBERG M, WEDEMEYER H: Current and future treatment of hepatitis C. Indian J. Gastroenterol (2001) 20:C47–051. [PubMed] [Google Scholar]
  • 65.BAKER DE: Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev. Gastroenterol Disord. (2003) 3:93–109. [PubMed] [Google Scholar]
  • 66.PEPINSKY RB, LEPAGE DJ, CHAKRABORTY A et al: Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. Pharmacol Exp. Ther. (2001) 297:1059–1066. [PubMed] [Google Scholar]
  • 67.LANG ZW, ZHANG LJ, ZHANG SJ et al.: A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology (2003) 35:526–531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.DE GROOT AS: How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past. Vaccine (2003) 21:4095–4104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.HO JC, 00I GC, MOK TY et al: High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Respic Grit. Care Med. (2003) 168:1449–1456. [DOI] [PubMed] [Google Scholar]
  • 70.GLASS WG, ROSENBERG HF, MURPHY PM: Chemokine regulation of inflammation during acute viral infection. Carr. Opin. Allergy Clin. Ingnunel (2003) 3:467–473. [DOI] [PubMed] [Google Scholar]
  • 71.GNIADEK P, AKTAS 0, WANDINGER KP et al: Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. Neureingnunel; (2003) 137:187-196. Websites [DOI] [PubMed] [Google Scholar]

Websites

  • 101.http://www.cdc.gov/ncidod/sars/ clinicalguidance.htm CDC guidance and recommendations for SARS .
  • 102.http://www.who.int/csr/sars/en WHO SARS website .

Articles from Expert Opinion on Biological Therapy are provided here courtesy of Taylor & Francis

RESOURCES